Home > Journals > Minerva Endocrinologica > Past Issues > Articles online first > Minerva Endocrinologica 2020 Jul 23

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Endocrinologica 2020 Jul 23

DOI: 10.23736/S0391-1977.20.03219-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials

Besmir NREU, Ilaria DICEMBRINI, Federico TINTI, Edoardo MANNUCCI, Matteo MONAMI

Diabetology, Careggi Hospital and University of Florence, Florence, Italy


PDF


AIM: An association between Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and risk of pancreatitis and pancreatic cancer has been suggested. Since its first description, several new trials (including three cardiovascular outcome trials) have been published, substantially increasing the available data set. This suggests the need for an update of the previous meta analysis.
MATERIALS AND METHODS: A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials, with duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placebo or any other non-GLP-1 receptor agonist drug. The endpoints were pancreatitis, pancreatic cancer reported as serious adverse events. Mantel-Haenszel odds ratio (MH-OR) with 95% Confidence Interval (95% CI) was calculated for all outcomes defined above, on an intention-to-treat basis.
RESULTS: A total of 43 trials fulfilling inclusion criteria (all reporting data on pancreatitis and pancreatic cancer) was identified. GLP-1 RA showed no association with pancreatitis (MH-OR 1.24 [0.94, 1.64]; p=0,13) and pancreatic cancer (MH-OR 1.28 [0.87, 1.89]; p=0,20).
CONCLUSIONS: No clear evidence of risk for pancreatitis was observed, whereas data on pancreatic cancer are too scarce to draw any conclusion.


KEY WORDS: Glucagon-like peptide-1 receptor agonists; Type 2 diabetes; Pancreatitis; Pancreatic cancer; Meta-analysis

top of page